最新一期业绩显示，2025年一季报，公司实现营业收入14.78亿元，同比1.59%；净利润7702.23万元， 同比177.86%，销售毛利率17.17%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)21蓝帆医疗-20.88-12.630.7056.30亿行业平均 50.6449.074.68109.10亿行业中值37.0537.632.5050.67亿1天益医疗-1817.92-3113.901.9423.17亿2澳华内 镜-726.69364.475.8276.58亿3诺唯赞-431.93-510.862.3792.43亿4爱朋医疗-431.66327.945.2035.42亿5博晖 创新-337.40535.413.6049.50亿6硕世生物-147.79-2159.571.3243.23亿7奥精医疗-142.33-208.621.8826.42亿 8睿昂基因-105.65-86.741.5013.67亿9康泰医学-87.85-74.223.1357.82亿10中红医疗-74.13-59.130.9451.52亿 11热景生物-67.89-78.225.01149.40亿 来源：金融界 6月 ...

Group 1 - The core business of the company includes cardiovascular, health protection, and nursing services, with major products being cardiovascular products, health protection products, and emergency rescue products [1] - The company has developed globally unique patented drugs, including BA9, and has generated over $300 million in patent licensing revenue [1] - The latest financial report for Q1 2025 shows a revenue of 1.478 billion yuan, a year-on-year increase of 1.59%, and a net profit of 77.0223 million yuan, a year-on-year increase of 177.86% [1] Group 2 - The company's current price-to-earnings (P/E) ratio is -19.98, with a price-to-book (P/B) ratio of 0.67 and a total market capitalization of 5.388 billion yuan [2] - The industry average P/E ratio is 48.92, while the industry median is 35.68, indicating that the company is significantly undervalued compared to its peers [2] - The company has a sales gross margin of 17.17% as per the latest financial results [1]